Skip to main content
. 2019 Jul 24;2019:7656747. doi: 10.1155/2019/7656747

Table 2.

Tumor response evaluation based on the WHO and RECIST criteria (stage 1: 15 patients; stage 2: 10 patients).

Response evaluation Stage 1 Stage 2
Cycle 2 (N = 15) Cycle 4 (N = 8) Cycle 2 (N = 10) Cycle 4 (N = 5)
WHO
 Partial response 1 0 0 0
 Stable disease 7 1 5 2
 Progressive disease 5 5 4 3
 Others 2 2 1 0
RECIST
 Partial response 0 0 0 0
 Stable disease 9 2 5 4
 Progressive disease 4 4 4 1
 Others 2 2 1 0

Partial response was unconfirmed and thus not counted as clinical benefit.